Wound Debridement Before the Vacuum: What Medicare Data Shows About Where NPWT Actually Sits in Care (2026)

1. What standard of care actually contains

Wound-care catalogs are good at making the last device in the pathway look like the pathway. Guidelines are not.

IWGDF’s 2023 wound-healing interventions guideline — part of the 2023 update set ⁴ — opens the recommendation list with a constraint that should be printed on every NPWT brochure: recommendations are adjunctive to best standard of care, and that standard includes sharp debridement and basic wound dressings that absorb exudate and maintain a moist environment ¹. Recommendation 1 tells clinicians not to substitute autolytic, biosurgical, hydrosurgical, chemical or laser debridement for that standard (strong recommendation, low-certainty evidence). Recommendation 28 says to consider NPWT as an adjunct for postsurgical diabetes-related foot wounds (conditional, low). Recommendation 28a says do not use NPWT as an adjunct for non-surgically related diabetes foot ulcers (strong, low) ¹.

NICE NG19, the English diabetic-foot guideline, lists the same ingredients as standard care ^{2 5}. Recommendation 1.5.4 names five elements: offloading, control of foot infection, control of ischaemia, wound debridement, wound dressings. Recommendation 1.5.5 then makes offloading concrete: offer non-removable casting to offload plantar neuropathic, non-ischaemic, uninfected forefoot and midfoot ulcers, and an alternative device until casting can be provided. Debridement in hospital (1.5.7) is restricted to the multidisciplinary foot service, using the technique that matches expertise, site and preference. Debridement in the community (1.5.8) is restricted to professionals with the relevant training and skills, continuing the person’s treatment plan. NPWT appears at 1.5.9: consider it after surgical debridement, on that service’s advice. Recommendation 1.5.10 then prices the dressing layer: when deciding about wound dressings and offloading, take account of clinical assessment and preference, and use devices and dressings with the lowest acquisition cost appropriate to the clinical circumstances ². That last sentence is a procurement constraint, not a cheap-goods slogan. A tender that jumps to a capital pump before it can name a debridement owner and a lowest-appropriate-cost dressing has skipped two numbered recommendations.

Two documents, two health systems, one sequence. Offloading and perfusion are not optional prefaces. Debridement is not a product code a factory ships. NPWT is allowed, and in both texts it is allowed after the wound bed has been prepared, not instead of preparation.

That is not an anti-NPWT argument. VEMERIX manufactures both an NPWT pump and a disposable NPWT dressing kit. It is a mix argument. If the clinical literature puts the vacuum in a gated box, a commercial strategy that opens every tender with the vacuum is selling against the guidance the buyer’s clinicians are supposed to follow.

The reason DFU is a real commercial conversation at all is not in the CMS extract. Zhang and colleagues’ 2017 meta-analysis put global diabetic-foot-ulcer prevalence among people with diabetes at 6.3% (95% CI 5.4–7.3), and North America at 13.0% (8.3–17.7) ⁶. That is a large at-risk population. It is not a licence to vacuum every ulcer. IWGDF 28a is written for exactly that population: non-surgical diabetes foot ulcers, where the evidence does not support NPWT as adjunct. Scale without sequence is how a catalog oversells the gated SKU.

2. The Medicare denominator

What this file is not

We analysed CMS Medicare Physician & Other Practitioners data, calendar years 2013–2024, national facility plus office, for the debridement family and the NPWT application/management family ³. The extract contains 20,830 rows. National rows are CMS pre-aggregates. CMS’s own methodology states that the file is 100% final-action physician/supplier Part B non-institutional line items for the Medicare FFS population, and that claims processed by a DMEPOS MAC are not included ⁷. Three limits belong up front, because they change what the numbers may be used to say.

Medicare fee-for-service only. Medicare Advantage is out of this file. So are Medicaid, commercial payers, the VA and cash-pay. The extract under-represents younger trauma and some working-age diabetic populations.

These are professional claim lines, not DME. A rented or purchased NPWT pump billed as durable medical equipment does not live here. Prior VEMERIX work used the same four NPWT application codes to measure durable-versus-disposable application share. This report uses it as care-path volume against debridement. Do not convert the professional-payment totals into “Medicare spends X on NPWT.”

total_services are lines. Add-on debridement codes bill extra area on the same encounter and inflate the debridement count. We therefore report all-lines totals and primary-depth totals separately. Neither is unique patients.

Lines, intensity and professional dollars

With those limits: debridement lines rose from 2.14 million in 2013 to 3.71 million in 2024 (+73.5%). NPWT application lines rose from 57,287 to a 2019 peak of 77,364, then sat at 67,221 in 2024 — 17% above 2013, 13% below peak ³.

The ratio is the finding. NPWT application per 1,000 debridement lines fell from 26.8 to 18.1 over the decade, a 32% decline in intensity ³. In 2024 there were about 55 debridement lines for every NPWT application line. Using only primary-depth debridement (2.65 million), the ratio is still about 39 to 1.

The decline is stepwise, not a one-year accident. Intensity was 26.8 in 2013, 24.7 in 2015, 22.5 in 2019, 19.8 in 2021 and 18.1 in 2024 ³. Every named year is lower than the last named year. Disposable NPWT codes appear in 2015, the same year intensity is already falling. They do not reverse the path.

Professional payments in the file — services times average Medicare payment — are about $270 million for debridement in 2024 versus about $2.9 million for NPWT application. That dollar gap is real inside this file and misleading as a headline, because DME rental is missing. The service-count gap does not have that problem. It is the billed professional work of preparing a wound versus applying a vacuum.

The path of those professional dollars is still worth one sentence of caution. Debridement’s estimated professional paid amount moved from about $151 million in 2013 to $270 million in 2024, roughly in line with line growth. NPWT application’s estimated professional paid amount moved from about $1.34 million to $2.93 million — more than doubling — while application lines rose only 17% ³. Implied professional dollars per NPWT line rose from about $23 to about $44. That is consistent with disposable application codes entering the file and with office NPWT carrying more professional payment than facility NPWT in 2024, and it is still not a DME total.

As an aggregate rate, the 2024 file contains about 18 NPWT application lines per 1,000 debridement lines ³. This is not a worked patient mix: the file does not link those lines into episodes, and debridement codes do not identify wound etiology or the dressing used afterward. The defensible conclusion is narrower: NPWT application is much less frequent in this professional-service dataset. Local episode-level claims, indications, utilization and inventory turns are still required before a buyer converts that observation into an order quantity.

Beneficiary sums in the extract — 775,972 on debridement codes, 38,139 on NPWT codes in 2024 — are not unique people. The same patient can generate multiple lines and multiple codes. They are still a directional scale check: the professional-service file sees an order-of-magnitude more debridement-coded beneficiary counts than NPWT-coded beneficiary counts ³.

COVID is visible as a pause, not a reset. Debridement lines were already 3.44 million in 2019 and 3.44 million in 2020, then climbed to 3.65 million in 2021, dipped to 3.58 million in 2022 and 3.57 million in 2023, and set the series high at 3.71 million in 2024 ³. NPWT application fell from the 2019 peak through 2022 (65,095) and only partly recovered. Whatever mix shift happened in 2020, the 2024 file still shows debridement as the expanding layer.

The people-and-provider cut says the same thing at a different grain, and one extra thing. Code-level beneficiary sums — not unique people — ran 599,882 on debridement codes in 2013 and 775,972 in 2024, against 29,415 and 38,139 on NPWT codes. Rendering providers in the file: 96,418 debridement versus 15,115 NPWT in 2013; 118,962 versus 21,890 in 2024 ³. Debridement billers grew about 23%; NPWT billers grew about 45%. About 5.4 clinicians bill a debridement code in this file for every clinician who bills an NPWT application code. Lines per rendering provider tell the frequency story the headcount hides. In 2024 a debridement biller in this file is associated with about 31 debridement lines; an NPWT biller with about 3 application lines ³. In 2013 those figures were about 22 and 3.8. Debridement got busier per biller. NPWT application did not. Intensity fell because debridement outran application, not because NPWT vanished from the roster.

Inside NPWT, the 2024 mix is still mostly durable application: 38,686 lines at ≤50 cm² and 14,359 at >50 cm², against 11,815 and 2,361 disposable ³. Durable application is 53,045 lines, 13% below its 2019 peak of 70,082. Disposable application is 14,176, up from zero before 2015. The pie did not grow enough to keep total application at the 2019 peak. Form-factor substitution happened on a shrinking-to-flat professional-application base. That is the disposable-shift report’s finding, restated here only so nobody reads the 55-to-1 ratio as “disposable NPWT never arrived.” It arrived. It did not become the volume layer.

Add-on area codes are a growing share of the debridement file, which is why this report carries two denominators. Primary-depth lines were 81.3% of all debridement lines in 2013 and 71.5% in 2024. Subcutaneous remained 77% of primary-depth volume in 2024, down from 83.5% in 2013; bone stayed about 4% ³. The file is not quietly becoming an operating-room bone book. It is becoming a slightly more add-on-heavy subcutaneous book. Using all-lines 55-to-1 without saying that is how a reader over-counts encounters. Using only 39-to-1 without saying add-ons exist is how a reader under-counts paperwork. Both numbers travel.

3. Most paid debridement is subcutaneous

If debridement were mostly operating-room bone work, NPWT would look like a peer. It is not.

In 2024, primary-depth lines split as 2,042,234 subcutaneous, 506,331 muscle/fascia and 104,380 bone ³. Subcutaneous is 77% of primary-depth volume. Bone is 4%. Add-on area lines add another 1.06 million claims on top of those encounters — 650,800 extra-area subcutaneous, 307,027 muscle/fascia, 97,435 bone — and they measure extra square centimetres, not extra people.

The decade shape of those depths is growth at every layer, not a migration into the operating room. Subcutaneous primary-depth lines rose from 1.45 million in 2013 to 2.04 million in 2024. Muscle/fascia rose from 226,452 to 506,331. Bone rose from 60,731 to 104,380 ³. Muscle/fascia more than doubled; it is still a quarter of subcutaneous. A catalog that treats “surgical debridement” as the typical Medicare line is reading the IWGDF NPWT box, not the claim file.

A single encounter can therefore look larger in the all-lines file than it is in the clinic. A subcutaneous debridement that needs two extra area add-ons becomes three claim lines and still one wound. That is why this report carries both denominators. The 55-to-1 all-lines ratio is the upper bound on debridement paperwork per NPWT application line. The 39-to-1 primary-depth ratio is closer to encounters, but still does not link the services or specify product demand.

This is wound-bed preparation at scale in the Medicare FFS population. It does not identify the wound type, the product used after debridement or the clinical appropriateness of NPWT for any individual claim. Deep, postsurgical defects — the IWGDF NPWT box — exist; the claim-line totals cannot show how many debridement lines belong to that subset.

Offloading is the honest missing lane. NICE puts non-removable casting for plantar neuropathic, non-ischaemic, uninfected forefoot and midfoot ulcers in standard care, ahead of NPWT ². This CMS extract has no offloading codes. We did not invent a boot-versus-vacuum ratio. The implication still stands: a device mix that jumps from “diabetic foot” to “vacuum” has skipped both debridement and the offloading NICE treats as first-line for a defined ulcer type. That skip is a clinical error and a stocking error.

4. Office versus facility

Place of service splits the two families.

In 2024, debridement was 52.2% office/non-facility and 47.8% facility. NPWT application was 73.1% facility and 26.9% office ³. That split is a trend, not a one-year snapshot. Debridement’s office share rose from 38.9% in 2013 to 52.2% in 2024, and first crossed half in 2021 (1.83 million office versus 1.82 million facility). NPWT application’s office share moved only from 21.9% to 26.9% over the same years, and actually dipped to 17.7% in 2019 before recovering ³. Facility NPWT application peaked at 63,639 lines in 2019 and sat at 49,146 in 2024. Office NPWT application rose from 12,565 to 18,075 — real growth, not enough to follow debridement out of the hospital.

Professional payment inside this file tells a related, narrower story. In 2024, office debridement carried about $179 million of the file’s estimated professional paid amount versus about $90 million in facility. Office NPWT application carried about $2.00 million versus about $0.92 million in facility — more professional payment on fewer office lines ³. That inversion is a form-factor clue (disposable application codes pay differently) and is still not a DME total. Do not quote it as “Medicare spends more on office vacuum than hospital vacuum.” Quote it as: even the professional-application dollars have started to follow the office, while the line count has not.

The setting split is consistent with NPWT being used selectively, but this file contains no diagnosis, wound etiology or surgical-status field. Facility NPWT may include postsurgical and higher-exudate work of the kind NICE and IWGDF discuss; the extract cannot prove that composition. In 2024 the office file is about 107 debridement lines per NPWT application line (1,936,381 / 18,075), while the facility file is about 36 to 1 (1,771,826 / 49,146) ³. Those are aggregate place-of-service ratios, not linked pathways or SKU requirements.

Single-use NPWT is the commercial attempt to move vacuum toward that office loop. Disposable application codes do not exist in this file in 2013–2014. They appear in 2015 at 2.6% of NPWT lines and reach 21.1% in 2024 (14,176 of 67,221) ³. That is the form-factor shift documented in VEMERIX’s disposable NPWT report. It ran in parallel with the intensity drop, not against it. Disposable share went up; NPWT per 1,000 debridement lines went down. Changing the pump did not make vacuum the volume layer.

5. State intensity is not volume

National ratios hide local heterogeneity.

We summed 2024 state-level debridement and NPWT application lines and computed NPWT per 1,000 debridement lines. States and the District of Columbia with fewer than 5,000 debridement lines are excluded from ranking: below that floor, a few hundred NPWT lines explode the ratio (Wyoming’s 306 per 1,000 sits on 1,074 debridement lines). Among the 47 jurisdictions that clear the floor, median intensity is 19.6 ³.

Volume leaders are not intensity leaders. California billed 612,968 debridement lines — the most in the country — at 8.1 NPWT per 1,000, among the lowest intensities. Florida, second in debridement volume at 540,048 lines, sits at 14.9. Mississippi is 5.7. Minnesota is 53.4; Wisconsin 51.8; the District of Columbia 65.5 on 9,407 debridement lines — above the ranking floor, still a small book ³. Utah (11.1 on 22,028 lines) and Maryland (11.9 on 83,652) sit with California in the low-intensity, real-volume group. South Dakota (44.2) and Nebraska (40.6) sit with Minnesota in the high-intensity, modest-volume group. Pennsylvania, at 27.2 on 105,485 debridement lines, is a large-state high-side exception: not Minnesota, not California.

Intensity is not quality of care, diabetic-foot incidence or an inventory ratio. Coding culture, wound-center density, surgical mix and how much NPWT is billed as DME rather than a professional application all move the number. It is useful as a hypothesis generator: it tells a distributor where to request local claims and utilization data before setting the mix. A single “US wound-care” forecast that assumes 18 NPWT lines per 1,000 debridement lines everywhere is averaging away meaningful local variation.

Four sketches from the same table ³:

• California: largest debridement book, 8.1 intensity. The professional file shows substantially less NPWT application relative to debridement than the national rate; ask for local episode, DME and inventory data before interpreting why.
• Mississippi: 5.7 intensity on a still-large debridement book (77,596 lines). Indiana is similar at 8.5 on 79,604 debridement lines. The same data request is needed.
• Minnesota / Wisconsin / New Hampshire: ~52–53 intensity, modest debridement volume (NH is 8,580 lines at 52.0). NPWT application is relatively more visible in the professional file; indication gates still apply, and the ratio still does not prescribe stock.
• Texas / New York: large debridement books (299,922 and 165,696) at 21.9 and 22.3 intensity — close to the large-state median. These are the customers for whom a national average is a decent prior, not a substitute for the buyer’s claims.
• Florida / Pennsylvania: Florida is the second-largest debridement book (540,048) at 14.9 intensity — California-shaped, slightly less so. Pennsylvania is 27.2 on 105,485 lines — a large-state high-side exception, not a Minnesota.
• National median among large states: 19.6. Use it as a prior only until the buyer’s own claims arrive.

None of these sketches is a protocol or a purchasing rule. They show relative billed professional application, not underlying clinical need. A tender should use the variation to ask better local questions, not multiply it into units.

The same table in absolute lines: if California’s 612,968 debridement lines ran at the national 18.1 aggregate rate, the file would show about 11,100 NPWT application lines there; it shows 4,940. Minnesota’s 24,384 debridement lines would correspond to about 440 at the national rate; the file shows 1,303 ³. Those gaps can reflect coding, setting, specialty structure, clinical mix and missing DME claims. They demonstrate heterogeneity, not how many units belong in a state warehouse.

6. The device file measures regulatory activity

Sharp debridement is a trained person’s time. It barely exists as a dedicated 510(k) class. We counted current FDA 510(k)s in three roles ⁸:

• NPWT devices: 235 clearances (1997–2026), of which 214 are powered suction pumps under 21 CFR 878.4780, Class II ⁹. The rest are related NPWT codes in the same landscape pull.
• Debridement-adjacent devices (jet lavage and ultrasound wound cleaners): 62.
• Conventional dressings and liquid bandage: 365, of which 222 are liquid-bandage rows, 107 occlusive dressings, 29 hydrogels, and a handful of hydrophilic / liquid-skin-protectant rows.

Do not read those counts as a market-share table. They are a map of what FDA has been asked to clear as a device. Sharp debridement barely appears because it is a clinician’s time.

The file is thick where manufacturers have sought 510(k) clearance: dressings and vacuum hardware. It is thin where guidelines put the first clinical act because sharp debridement is usually a service, not a device submission. Hydrosurgical and ultrasonic debriders exist; IWGDF tells clinicians not to use them over sharp debridement as standard of care ¹. That explains why the sources describe different objects. Clearance counts do not validate a care sequence, measure current catalogs, sales or demand.

The vintage of those clearances differs from the claim-line trend. Of 365 dressing and liquid-bandage 510(k)s, 5 have decision dates in 2015–2026. Of 235 NPWT-device 510(k)s, 144 do. Jet-lavage and ultrasound-cleaner clearances split 46 / 16 ⁸. Decision-year counts in the dressing pull peak at 38 in 1994 and 37 in 1995, and the 1992–1999 window alone is 194 clearances ⁸. This shows where recent regulatory submissions occurred; it does not say whether older products remain marketed or how many dressings are used after debridement.

The 365 dressing-and-liquid-bandage clearances are a regulatory-history count, not evidence that any particular dressing can follow the 2.04 million subcutaneous debridement lines ^{8 3}. Product indication, wound depth, exudate, infection status and local registration still decide suitability. The actionable sequence comes from the clinical guidance; the FDA count only describes submission activity.

MAUDE follows exposure. Powered NPWT suction pumps account for 9,173 report rows in this snapshot; jet-lavage devices account for 4,791. NPWT event mix in the pump-and-related slice is malfunction 5,800, injury 3,275, death 75. The debridement-adjacent slice is malfunction-heavy: 4,438 malfunction, 334 injury, 6 death ¹⁰. That is not a reason to call debridement “safer.” Sharp debridement is mostly not a coded device, so it does not accumulate device reports. Use the FDA file as a map of what is sold as a device, not as a league table of harm.

7. Read NPWT indications without overselling

The honest NPWT claim in 2026 is narrower than most product pages.

IWGDF: consider it for postsurgical diabetes-related foot wounds; do not use it as adjunct for non-surgical diabetes foot ulcers ¹. NICE: consider it after surgical debridement, on multidisciplinary advice ². Evidence certainty in IWGDF is often low; the strength of 28a is still “strong.” Low-certainty evidence plus a strong “do not routinely” is a procurement constraint, not a loophole.

That constraint is compatible with selling NPWT. It is incompatible with selling NPWT as the default for every diabetic foot ulcer that walks into clinic. In a distributor conversation the useful translation is: ask whether the wound has been surgically debrided and whether a multidisciplinary foot service (or the local equivalent) has authorized vacuum. If the answer is “it is a DFU, so we vacuum,” IWGDF 28a is the objection, not a competitor’s brochure ¹. If the answer is “postsurgical, authorized,” NPWT is in-scope and the next question is durable versus disposable setting, which is the other report ¹¹.

The disposable-shift report remains the right place to read durable-versus-single-use application share, pump-versus-dressing economics, and why a registered kit matters ¹¹. This report’s job is to stop that form-factor story from being mistaken for the whole wound pathway.

Dressing selection and regulatory class are also not this article. See VEMERIX’s wound-dressing classification and NPWT dressing selection for those forks ^{12 13}. The point here is order: class and kit evidence come after the buyer has admitted that most paid work is debridement plus a dressing.

8. A stocking and tender sequence

If guidelines and Medicare volume agree, the tender should agree.

First, name debridement as a service. Who may debride in hospital versus community, with which training, is a NICE requirement ². A device tender that cannot point to that ownership is a catalog, not a pathway. Exporters cannot staff the US clinic; they can stop pretending a pump substitutes for that staff.

Second, specify registered dressings that actually do the IWGDF job: absorb exudate, keep a moist environment, with a truthful claim and a class that matches the claim ^{1 12}. “Advanced wound care” as a line item is too vague to establish that fit. The 2.65 million primary-depth lines establish service scale, not units of any dressing.

Third, add NPWT with indication gates. Postsurgical, MDFT-advised, not a default checkbox for non-surgical DFU ^{1 2}. Durable versus disposable is a setting choice inside that gate, documented elsewhere ¹¹. Tender language that asks for both a pump and a disposable kit without an indication rule will be used as a vacuum shopping list.

Fourth, match setting and state. Use the intensity map to identify where national assumptions need local claims, DME, utilization and inventory data. It is neither a quality score nor a SKU multiplier ³.

Copy-ready questions for an RFQ:

• Which wounds in this contract are expected to receive sharp debridement, by whom, how often?
• Which dressing claims and sizes cover the subcutaneous majority?
• For which listed indications is NPWT allowed, and who authorizes it?
• What share of use is facility versus office in the last year of local data, if the buyer has any?

If the answers are “we need a vacuum” four times, the pathway has not been specified.

9. Where VEMERIX fits

VEMERIX is Weihai Medison’s export brand for a minimally invasive platform. On the wound side that means an NMPA Class II medical vacuum NPWT pump and a Class II disposable NPWT drainage dressing kit, plus wound-and-skin consumables (including a liquid bandage and medical adhesive). It does not mean a portfolio-wide CE mark. It does not mean a clinical-superiority claim against any named NPWT system.

The fit to this evidence is unglamorous and usable. VEMERIX can supply products that sit on a debridement pathway; it cannot sell debridement. The pump is Class II (NMPA Lu Mech Reg. 20182140303) with a published pressure range of −50 to −450 mmHg and leak, overflow and overheat alarms; the dressing kit is Class II with a defined foam and drainage architecture ^{14 15}. The pump listing itself treats unfinished debridement as a contraindication. VEMERIX also lists a Class II hyaluronic liquid bandage (Lu Mech Reg. 20180123), but its published use is limited to minor wounds and it is contraindicated for non-minor wounds, large abrasions and deep cuts ¹⁶. It must not be presented as the default dressing after chronic-wound debridement or as a proxy for a diabetic-foot dressing. A distributor should match each registered SKU to the local indication and buyer protocol, with NPWT retained as a gated adjunct rather than the pathway itself.

We did not pull UN Comtrade into this piece. Dressing HS chapters mix retail bandages with hospital kits and do not observe debridement. An empty lane is a finding: trade flows will not rescue a care-path argument that Medicare and IWGDF already make.

Due diligence on how those devices are made still starts with the contract-manufacturing evidence checklist. This report does not replace it.

10. Wound debridement and NPWT FAQ

Does this mean NPWT volume is collapsing? No. Application lines in 2024 are still above 2013. They are below the 2019 peak, and they have lost intensity relative to debridement ³.

Why not use DME data for NPWT? This extract is the professional-service file. DME rental would raise NPWT spend and would not erase the application-versus-debridement line gap. We do not invent a DME total we did not compute.

Is 3.71 million unique patients? No. It is claim lines, including add-on area codes. Primary-depth lines are 2.65 million. Beneficiary sums across codes are not unique people ³.

Does IWGDF ban NPWT on diabetic feet? No. It supports considering NPWT on postsurgical diabetes-related foot wounds and recommends against it as adjunct on non-surgical diabetes foot ulcers ¹.

Should we stop selling pumps into California? No. California is the largest debridement market and a low-intensity NPWT market. That is a mix signal: more dressing capacity per vacuum, not a boycott ³.

Is the national 55-to-1 ratio the office ratio? No. Office debridement-to-NPWT is about 107-to-1 in 2024; facility is about 36-to-1 ³.

Do hydrosurgical debriders replace scalpels in this story? IWGDF says not over standard of care ¹. The 510(k) class is small next to dressings and NPWT pumps ⁸.

What should a private-label buyer put on the first purchase order? This claims file cannot prescribe a first purchase order. The buyer should first map local wound types, episodes, existing inventory turns and registered indications; then select indicated dressings and gate NPWT to the protocol and authorizing service ^{1 2 12}.

Is this the same as the disposable NPWT report? No. That report is form factor inside NPWT. This report is NPWT’s place in the billed pathway relative to debridement.

Did disposable NPWT reverse the intensity drop? No. Disposable codes reached 21.1% of NPWT lines in 2024 while intensity fell from 26.8 to 18.1 per 1,000 debridement lines ³.

Why do you quote both 55-to-1 and 39-to-1? Add-on area codes grew from 18.7% of debridement lines in 2013 to 28.5% in 2024. 55-to-1 is all lines; 39-to-1 is primary-depth only ³.

Is offloading in this Medicare file? No. NICE 1.5.5 still puts non-removable casting in standard care for a defined ulcer type ². We did not invent a boot-versus-vacuum ratio.

Who is allowed to debride? NICE 1.5.7 restricts hospital debridement to the multidisciplinary foot service. 1.5.8 restricts community debridement to professionals with the relevant training and skills ². A device catalog cannot answer that question.

Does NICE tell buyers to purchase the cheapest dressing? It tells them to use devices and dressings with the lowest acquisition cost appropriate to the clinical circumstances (1.5.10) ². That is not a licence to substitute an unregistered SKU.

Is 21 CFR 878.4780 a US NPWT product-code dump? No. It is the Class II regulation for powered suction pumps. This article uses it as the classification home of 214 of 235 NPWT-device 510(k)s, without treating a regulation number as a brand ^{9 8}.

Conclusion

Guidelines put sharp debridement and a dressing in standard of care and put NPWT in a gated box. Medicare FFS professional data, with all the limits stated above, show that debridement lines are more numerous and more office-weighted than NPWT application lines, and that their aggregate ratio varies substantially by state. The data do not link episodes and cannot prescribe a SKU plan.

Buy the path. Specify who debrides, which dressings follow, and which wounds may see a vacuum. VEMERIX belongs in the second and third of those sentences. It does not belong in a story where the pump is the pathway.